Charles Schwab Trust Co Trims Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Charles Schwab Trust Co trimmed its holdings in Zoetis Inc. (NYSE:ZTSFree Report) by 5.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,061 shares of the company’s stock after selling 170 shares during the quarter. Charles Schwab Trust Co’s holdings in Zoetis were worth $604,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of ZTS. Evermay Wealth Management LLC boosted its stake in shares of Zoetis by 439.3% during the first quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock worth $25,000 after buying an additional 123 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its holdings in shares of Zoetis by 430.8% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 112 shares during the period. Worth Asset Management LLC purchased a new stake in shares of Zoetis during the first quarter worth approximately $26,000. VisionPoint Advisory Group LLC acquired a new position in Zoetis in the 2nd quarter valued at $29,000. Finally, Moisand Fitzgerald Tamayo LLC raised its position in Zoetis by 105.5% during the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after buying an additional 96 shares during the last quarter. 89.47% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ZTS. cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Barclays raised their price target on shares of Zoetis from $255.00 to $260.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 14th. The Goldman Sachs Group raised their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Stifel Nicolaus raised their price objective on Zoetis from $195.00 to $215.00 and gave the stock a “buy” rating in a report on Friday, January 12th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $230.00 price target on shares of Zoetis in a research report on Tuesday, December 19th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $224.33.

Read Our Latest Research Report on ZTS

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 363 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the sale, the executive vice president now owns 20,417 shares of the company’s stock, valued at $4,037,257.58. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.12% of the company’s stock.

Zoetis Stock Down 0.8 %

ZTS stock opened at $172.57 on Monday. The firm’s 50-day moving average is $190.23 and its two-hundred day moving average is $183.33. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The company has a market capitalization of $79.01 billion, a price-to-earnings ratio of 34.04, a price-to-earnings-growth ratio of 2.69 and a beta of 0.87. Zoetis Inc. has a 52 week low of $151.03 and a 52 week high of $201.92.

Zoetis (NYSE:ZTSGet Free Report) last issued its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The firm had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.15 EPS. On average, analysts forecast that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Investors of record on Friday, April 19th will be issued a $0.432 dividend. This represents a $1.73 dividend on an annualized basis and a yield of 1.00%. The ex-dividend date of this dividend is Thursday, April 18th. Zoetis’s dividend payout ratio is presently 33.93%.

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

See Also

Want to see what other hedge funds are holding ZTS? Visit to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with's FREE daily email newsletter.